---
document_datetime: 2024-01-10 10:29:07
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ritonavir-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: ritonavir-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.2047737
conversion_datetime: 2025-12-30 02:32:24.771654
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ritonavir Mylan

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0020/G            | This was an application for a group of variations. | 09/01/2024                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH   |            |            |                        |                                                                                                                                                                                                                              |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0019   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                                                                                              | 28/08/2023 | n/a        |                        |                                                                                                                                                                                                                              |
| IAIN/0018 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                            | 17/05/2023 |            | SmPC and PL            |                                                                                                                                                                                                                              |
| IAIN/0017 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                        | 31/01/2023 | n/a        |                        |                                                                                                                                                                                                                              |
| IA/0016   | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                               | 06/12/2022 | n/a        |                        |                                                                                                                                                                                                                              |
| R/0015    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                   | 23/06/2022 | 22/08/2022 | SmPC, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Ritonavir Mylan in the approved indication remains favourable and therefore recommended the renewal of the |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |            |                        | marketing authorisation with unlimited validity.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------|
| IB/0014/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within | 05/05/2022 | 22/08/2022 | SmPC, Labelling and PL |                                                    |
| T/0013    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 24/09/2021 | 18/11/2021 | SmPC, Labelling and PL |                                                    |
| IB/0012/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 08/09/2021 | 18/11/2021 | SmPC, Labelling and PL |                                                    |

<div style=\"page-break-after: always\"></div>

|           | assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                           |            |            |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0011   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 16/02/2021 | 18/11/2021 | Annex II and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IA/0010   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 07/01/2021 | n/a        |                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0007/G | This was an application for a group of variations. B.II.a.3.b.1 - Changes in the composition (excipients) of the finished product - Other excipients - Any minor adjustment of the quantitative composition of the finished product with respect to excipients B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold | 06/11/2020 | 21/04/2021 | SmPC and PL     | The SmPC sections 3, 6.3 and 6.5 have been updated as follows: 3. PHARMACEUTICAL FORM Film coated tablet (tablet). Yellow, capsule shaped, biconvex, beveled edge film coated tablet, approximately 19.1 mm x 10.2 mm, debossed with 'M163' on one side and plain blank on the other side. 6.3 Shelf-life 18 months. After first opening, use within 45 days. 6.5 Nature and contents of container HDPE bottle with polypropylene screw cap with aluminium induction sealing liner wad and a desiccant. |

<div style=\"page-break-after: always\"></div>

|           | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms   |            |            |                                  | The Labelling and Package Leaflet have been updated accordingly.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|--------------------------------------------------------------------|
| IB/0009   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                    | 25/03/2020 | 21/04/2021 | SmPC and PL                      |                                                                    |
| IAIN/0008 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                          | 26/02/2020 | 21/04/2021 | Annex II and PL                  |                                                                    |
| IB/0006/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference                                                                                                                                                                                                                                                                                                                                                               | 15/10/2019 | 14/11/2019 | SmPC, Annex II, Labelling and PL |                                                                    |

<div style=\"page-break-after: always\"></div>

|           | product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by   |            |     |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0005/G | This was an application for a group of variations. B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 12/06/2019 | n/a |

<div style=\"page-break-after: always\"></div>

|           | B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer        |            |            |                        |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| N/0004    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                   | 15/03/2019 | 06/05/2019 | PL                     |
| IAIN/0003 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                     | 27/11/2018 | 06/05/2019 | SmPC                   |
| IB/0002   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                     | 09/07/2018 | 06/05/2019 | SmPC, Labelling and PL |
| IAIN/0001 | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes | 03/05/2018 | 06/05/2019 | SmPC, Labelling and PL |